Lykos, formerly MAPS PBC, is on a mission to transform mental healthcare. The Company aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain committed to the rigorous pursuit of evidence-based development of novel approaches. Founded in 2014 by the non-profit MAPS, Lykos Therapeutics is a for-profit public benefit corporation ("PBC") established to further the development of investigational psychedelic-assisted therapies. As a PBC, Lykos considerers the impact of it's decisions on society just as the company thinks about it's financial implications. Everything Lykos does is viewed through a public benefit lens.